Information Density: U.S. Food and Drug Administration – Signal Evidence & AI Readability

U.S. Food and Drug Administration

(https://www.fda.gov) 📸 Data Snapshot: May 19, 2026
Information Density — The Lens

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Info Density Power-words vs. Substance ratio.
30 Impact Weight: 30 / 100
100% Reputation

The site exhibits zero heading fluff, with H1 and H4 tags utilizing high-specificity nouns and technical terms like ‘Post-Market Assessment Program,’ ‘BHT, ADA,’ and ‘National Priority Voucher Pilot Program.’ Body text maintains a high substance ratio, citing ‘chemical contaminants in infant formula’ and specific gene therapy treatments for ‘genetic hearing loss.’ There is no evidence of concept repetition; every press announcement and featured topic introduces distinct, measurable regulatory actions. Specificity is maximized through the use of exact dates (May 12, 2026) and specific legal/technical frameworks (483s, EUAs, 510Ks).

Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.

📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://www.fda.gov) U.S. Food and Drug Administration
Topic Paragraphs

[IMG: Woman looking at cans of infant formula in a store]

[H1] FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.

The FDA announced results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market. While breast milk is widely considered the gold standard and optimal source of nutrition for infants whenever possible, millions of parents depend on formula.

[H3] Featured Topics

Recalls

Report a Problem

Warning Letters

Consumer Updates

483s

EUAs

510Ks

Guidance Documents

Drug Databases

Import Program

[H3] FDA in Action

FDA Voices: How FDA is Implementing Landmark Cosmetics Legislation to Positively Impact Public Health

FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development

FDA Takes Action to Advance Gene Therapy Development

FDA PreCheck Pilot Program Strengthens Domestic Pharmaceutical Manufacturing

Agency Unveils Real-Time Trial Proofs-of-Concept and Upcoming Pilot Program

FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss

[H3] Press Announcements

May 12, 2026
[H4]
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

May 11, 2026
[H4]
FDA Advances Drug Repurposing to Address Unmet Medical Needs

May 08, 2026
[H4]
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

Newsroom

[H3] Products We Regulate

Food

Drugs

Medical Devices

Radiation-Emitting Products

Vaccines, Blood, and Biologics

Animal and Veterinary

Cosmetics

Tobacco Products
1977 chars
SUB-PAGE · THIN (https://fda.gov/about-fda/about-website/language-assistance-services/)
Not found
9 chars
SUB-PAGE · THIN (https://fda.gov/about-fda/contact-fda/)
Not found
9 chars
SUB-PAGE · THIN (https://fda.gov/about-fda/)
Not found
9 chars
SUB-PAGE · THIN (https://fda.gov/regulatory-information/search-fda-guidance-documents/)
Not found
9 chars
SUB-PAGE · THIN (https://fda.gov/safety/recalls-market-withdrawals-safety-alerts/)
Not found
9 chars
🧭 Industry Context — common generic-claim patterns in Government, Municipal & Public Sector to weigh the text against
Generic Claims: serving our community, committed to transparency, working for you, building a better future for all, your voice matters, accountable to the people…
Red Flags: no published financial data, no meeting minutes or decision records, contact information that leads to dead ends, claims of transparency without published data, no complaints or feedback mechanism, outdated information across service pages…
Semantic Drift Patterns: homepage claims digital-first but most services require in-person visits, transparency commitment but no meeting minutes published, citizen engagement language but no consultation mechanisms, claims efficiency but service pages show bureaucratic processes…
Proof Expectations: published budgets and financial statements, council meeting minutes and agendas, performance metrics and service delivery data, FOI response rates and timelines, elected official contact information and records, audit reports and compliance documentation…
Explore the other reputation pillars for U.S. Food and Drug Administration